Incidences of exacerbations/new-onset cases of IBD in patients with/without a history of IBD at baseline, respectively
PsO cohort (n=5181) | PsA cohort (n=1380) | AS cohort (n=794) | |
History of IBD at baseline * | |||
History of CD, n (%)† | 5 (0.1%) | 2 (0.14%) | 5 (0.63%) |
Exacerbation of CD during study treatment, n | 2 | 0 | 3 |
History of UC, n (%)† | 10 (0.19%) | 2 (0.14%) | 3 (0.38%) |
Exacerbation of UC during study treatment, n | 4 | 1 | 1 |
History of IBDU, n (%)† | 0 | 4 (0.29%) | 17 (2.14%) |
Exacerbation of IBDU during study treatment, n | 0 | 0 | 0 |
New onset cases of IBD‡ | |||
Total number of new-onset cases of CD, n (%)§ | 3 (0.06%) | 3 (0.22%) | 5 (0.63%) |
Relapses, n | 1 | 0 | 0 |
Total number of new-onset cases of UC, n (%)§ | 10 (0.19%) | 2 (0.14%) | 3 (0.38%) |
Relapses, n | 0 | 0 | 0 |
Total number of new-onset cases of IBDU, n (%)§ | 1 (0.02%) | 2 (0.14%) | 1 (0.13%) |
Relapses, n | 0 | 0 | 0 |
*A history of IBD was physician-assessed based on patient history at baseline.
†Medical history percentages are based on n.
‡New-onset cases of IBD were IBD events occuring in patients with no prior history of IBD at baseline.
§New-onset of AE percentages are based on n.
AS, ankylosing spondylitis; CD, Crohn’s disease; IBD, inflammatory bowel disease; IBDU, IBD-unclassified; PsA, psoriatic arthritis; PsO, psoriasis; UC, ulcerative colitis.